166 related articles for article (PubMed ID: 34755992)
1. Dermatoscopy and locally advanced or multiple basal cell carcinomas: a non-invasive tool to evaluate sonidegib effectiveness.
Conforti C; Toffoli L; Agozzino M; Di Meo N; Zelin E; Zalaudek I
Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755992
[No Abstract] [Full Text] [Related]
2. Sonidegib with and Without Adjunctive Treatment for Locally Advanced Basal Cell Carcinomas.
Villani A; Fabbrocini G; Costa C; Potestio L; Scalvenzi M
Oncologist; 2022 Jun; 27(6):e533. PubMed ID: 35436344
[No Abstract] [Full Text] [Related]
3. Sonidegib (Odomzo°) and extensive basal cell carcinoma.
Prescrire Int; 2017 Jan; 26(178):14-15. PubMed ID: 30730637
[No Abstract] [Full Text] [Related]
4. Anal and rectal locally advanced basal cell carcinoma treated with sonidegib.
Conforti C; Toffoli L; Degrassi F; di Meo N; Zalaudek I
Dermatol Ther; 2022 Feb; 35(2):e15242. PubMed ID: 34854197
[No Abstract] [Full Text] [Related]
5. Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial.
Chen L; Aria AB; Silapunt S; Lee HH; Migden MR
Future Oncol; 2018 Mar; 14(6):515-525. PubMed ID: 29119833
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42 months.
Dummer R; Lear JT; Guminski A; Leow LJ; Squittieri N; Migden M
J Am Acad Dermatol; 2021 Apr; 84(4):1162-1164. PubMed ID: 33358380
[No Abstract] [Full Text] [Related]
7. Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update.
Chen L; Silapunt S; Migden MR
Future Oncol; 2016 Sep; 12(18):2095-105. PubMed ID: 27189494
[TBL] [Abstract][Full Text] [Related]
8. Effective management of infiltrative locally advanced basal cell carcinoma of the tibia with sonidegib.
Venturi F; Lambertini M; Melotti B; De Paolis M; Dika E
Int J Dermatol; 2024 May; 63(5):685-687. PubMed ID: 38351632
[No Abstract] [Full Text] [Related]
9. Clinical Clearance Following Improvement of Histologic Subtype of Basal Cell Carcinoma with Sonidegib.
Leow LJ; Howard V
Acta Derm Venereol; 2022 Nov; 102():adv00809. PubMed ID: 36281813
[No Abstract] [Full Text] [Related]
10. The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma.
Collier NJ; Ali FR; Lear JT
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1011-8. PubMed ID: 27636236
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.
Lear JT; Migden MR; Lewis KD; Chang ALS; Guminski A; Gutzmer R; Dirix L; Combemale P; Stratigos A; Plummer R; Castro H; Yi T; Mone M; Zhou J; Trefzer U; Kaatz M; Loquai C; Kudchadkar R; Sellami D; Dummer R
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):372-381. PubMed ID: 28846163
[TBL] [Abstract][Full Text] [Related]
12. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR
J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394
[TBL] [Abstract][Full Text] [Related]
13. Odomzo
Gupta AK; Mays RR; Abramovits W; Vincent KD
Skinmed; 2018; 16(1):35-38. PubMed ID: 29551110
[No Abstract] [Full Text] [Related]
14. Dynamic optical coherence tomography evaluation in locally advanced basal cell carcinoma during sonidegib treatment.
Cantisani C; Musolff N; Longo C; Di Guardo A; Rovaldi E; Rossi G; Sasso F; Farnetani F; Rega F; Bánvölgyiv A; Azzella G; Paolino G; Pellacani G
J Eur Acad Dermatol Venereol; 2024 May; 38(5):967-973. PubMed ID: 38270330
[TBL] [Abstract][Full Text] [Related]
15. Dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor sonidegib to manage adverse effects: A retrospective case series.
Villani A; Costa C; Fabbrocini G; Ruggiero A; Scalvenzi M
J Am Acad Dermatol; 2021 Apr; 84(4):e211-e212. PubMed ID: 33301802
[No Abstract] [Full Text] [Related]
16. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
Danial C; Sarin KY; Oro AE; Chang AL
Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
[TBL] [Abstract][Full Text] [Related]
17. Complete remission of an advanced basal cell carcinoma after only 3-month treatment with sonidegib: Report of a case and drug management during COVID-19 pandemic.
Villani A; Fabbrocini G; Costa C; Scalvenzi M
Dermatol Ther; 2020 Nov; 33(6):e14200. PubMed ID: 32870541
[No Abstract] [Full Text] [Related]
18. Hedgehog Pathway Inhibition.
Sekulic A; Von Hoff D
Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
[TBL] [Abstract][Full Text] [Related]
19. Drug-related adverse effects of vismodegib and sonidegib for locally advanced or metastatic basal cell carcinoma.
Gibson M; Murrell DF
Australas J Dermatol; 2020 May; 61(2):176-177. PubMed ID: 31747714
[No Abstract] [Full Text] [Related]
20. Fast evaluation and monitoring of ingenol mebutate treatment of multiple basal cell carcinomas by in vivo hand-held reflectance confocal microscopy.
Manubens E; Barreiro A; Bennassar A; Podlipnik S; Moreno N; Iglesias P; Malvehy J; Puig S
J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):e284-e286. PubMed ID: 27859830
[No Abstract] [Full Text] [Related]
[Next] [New Search]
